Immix Biopharma, Inc. IMMX Grants receivable
Grants receivable at other companies
Other financials
Where this comes from
Reported directly by Immix Biopharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:GrantsReceivable.
The official record: Immix Biopharma, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Immix Biopharma, Inc.'s grants receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Immix Biopharma, Inc.'s grants receivable?
- Immix Biopharma, Inc. (IMMX) reported grants receivable of $6.2M in Q1 2026.
- How has Immix Biopharma, Inc.'s grants receivable changed year-over-year?
- Immix Biopharma, Inc.'s grants receivable increased by 264.7% year-over-year, from $1.7M to $6.2M.
- What does grants receivable mean?
- This represents the amount of funding expected from government agencies or private foundations for research activities that has been earned but not yet collected. It indicates the company's success in securing non-dilutive funding to support its clinical pipeline. This asset highlights the reliance on external research grants as a source of working capital.